From the Departments of Cardiology (I.v.d.B, D.H., R.v.d.B., A.W.) and Intensive Care (J.H.), Academic Medical Center Amsterdam; Department of Cardiology (M.-J.C.), University Medical Center Utrecht; Departments of Intensive Care (M.v.d.J.), Neurology (F.v.K.), and Cardiology (F.t.C.), Erasmus Medical Center Rotterdam; Departments of Intensive Care (J.M.), Cardiology (M.v.d.B.), and Neurosurgery (R.G.), University Medical Center Groningen; Departments of Cardiology (O.K.) and Intensive Care (J.G.), VU University Medical Center; Department of Cardiology (M.G.), Haga Hospital The Hague; Department of Neurosurgical Center Amsterdam (P.V.), Academic Medical Center and VU University Medical Center; Department of Clinical Epidemiology (A.A.), Julius Center for Health Sciences and Primary Care; Departments of Neurology and Neurosurgery (A.A., G.R.), Utrecht Stroke Center, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht; and Stichting CardioZorg (F.V.), Amsterdam, the Netherlands.
Neurology. 2014 Jan 28;82(4):351-8. doi: 10.1212/WNL.0000000000000057. Epub 2013 Dec 20.
To assess whether cardiac abnormalities after aneurysmal subarachnoid hemorrhage (aSAH) are associated with delayed cerebral ischemia (DCI) and clinical outcome, independent from known clinical risk factors for these outcomes.
In a prospective, multicenter cohort study, we performed echocardiography and ECG and measured biochemical markers for myocardial damage in patients with aSAH. Outcomes were DCI, death, and poor clinical outcome (death or dependency for activities of daily living) at 3 months. With multivariable Poisson regression analysis, we calculated risk ratios (RRs) with corresponding 95% confidence intervals. We used survival analysis to assess cumulative percentage of death in patients with and without echocardiographic wall motion abnormalities (WMAs).
We included 301 patients with a mean age of 57 years; 70% were women. A wall motion score index ≥1.2 had an adjusted RR of 1.2 (0.9-1.6) for DCI, 1.9 (1.1-3.3) for death, and 1.8 (1.1-3.0) for poor outcome. Midventricular WMAs had adjusted RRs of 1.1 (0.8-1.4) for DCI, 2.3 (1.4-3.8) for death, and 2.2 (1.4-3.5) for poor outcome. For apical WMAs, adjusted RRs were 1.3 (1.1-1.7) for DCI, 1.5 (0.8-2.7) for death, and 1.4 (0.8-2.5) for poor outcome. Elevated troponin T levels, ST-segment changes, and low voltage on the admission ECGs had a univariable association with death but were not independent predictors for outcome.
WMAs are independent risk factors for clinical outcome after aSAH. This relation is partly explained by a higher risk of DCI. Further study should aim at treatment strategies for these aSAH-related cardiac abnormalities to improve clinical outcome.
评估动脉瘤性蛛网膜下腔出血(aSAH)后心脏异常是否与迟发性脑缺血(DCI)和临床结局相关,而与这些结局的已知临床危险因素无关。
在一项前瞻性、多中心队列研究中,我们对 aSAH 患者进行了超声心动图和心电图检查,并测量了心肌损伤的生化标志物。结局为 3 个月时的 DCI、死亡和临床结局不良(死亡或日常生活活动依赖)。采用多变量泊松回归分析,计算风险比(RR)及其相应的 95%置信区间。我们使用生存分析评估有无超声心动图壁运动异常(WMA)患者的死亡累积百分比。
我们纳入了 301 名平均年龄为 57 岁的患者;70%为女性。壁运动评分指数≥1.2 与 DCI 的调整 RR 为 1.2(0.9-1.6),死亡的 RR 为 1.9(1.1-3.3),临床结局不良的 RR 为 1.8(1.1-3.0)。中室壁 WMA 的调整 RR 为 DCI 1.1(0.8-1.4),死亡 2.3(1.4-3.8),临床结局不良 2.2(1.4-3.5)。心尖壁 WMA 的调整 RR 为 DCI 1.3(1.1-1.7),死亡 1.5(0.8-2.7),临床结局不良 1.4(0.8-2.5)。入院时心电图上的肌钙蛋白 T 水平升高、ST 段改变和低电压与死亡有单变量关联,但不是结局的独立预测因素。
WMA 是 aSAH 后临床结局的独立危险因素。这种关系部分是由 DCI 风险增加解释的。进一步的研究应旨在针对这些与 aSAH 相关的心脏异常制定治疗策略,以改善临床结局。